Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells $16,872.49 in Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Peter Greenleaf sold 797 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $21.17, for a total value of $16,872.49. Following the completion of the transaction, the director owned 23,087 shares of the company’s stock, valued at $488,751.79. This trade represents a 3.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Trading Up 4.8%

NYSEAMERICAN PTHS traded up $0.98 on Tuesday, hitting $21.48. 42,943 shares of the company were exchanged, compared to its average volume of 30,248. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.98 and a quick ratio of 1.31. Pelthos Therapeutics Inc. has a twelve month low of $18.19 and a twelve month high of $37.50. The firm has a market capitalization of $82.27 million, a P/E ratio of -0.98 and a beta of 3.07. The company’s 50 day moving average price is $24.74 and its 200-day moving average price is $25.21.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last announced its earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. The firm had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. Analysts predict that Pelthos Therapeutics Inc. will post -15.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Oppenheimer cut their target price on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a research note on Friday, August 14th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $55.40.

Institutional Investors Weigh In On Pelthos Therapeutics

An institutional investor recently raised its position in Pelthos Therapeutics stock. Knott David M Jr grew its holdings in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 9.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,073 shares of the company’s stock after purchasing an additional 1,792 shares during the period. Knott David M Jr owned about 0.63% of Pelthos Therapeutics worth $443,000 as of its most recent SEC filing. 77.96% of the stock is owned by hedge funds and other institutional investors.

About Pelthos Therapeutics

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company’s work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company’s specific product pipeline, operating history, geographic reach and leadership is limited.